Results 11 to 20 of about 2,198,545 (274)

Evaluation of cognitive function in the Dog Aging Project: associations with baseline canine characteristics

open access: yesScientific Reports, 2022
Canine cognitive dysfunction (CCD) is a neurodegenerative disease in aging dogs. It has been described previously in relatively small cohorts of dogs using multiple different rating scales.
Sarah Yarborough   +3 more
doaj   +1 more source

Implementation and review of the care ecosystem in an integrated healthcare system

open access: yesBMC Geriatrics, 2023
Background and objectives The University of California, San Francisco Memory and Aging Center (UCSF-MAC) led the development and tested a collaborative care model delivered by lay care team navigators (CTNs) with support from a multidisciplinary team ...
Michael H. Rosenbloom   +10 more
doaj   +1 more source

Coenzyme A binding sites induce proximal acylation across protein families

open access: yesScientific Reports, 2023
Lysine Nɛ-acylations, such as acetylation or succinylation, are post-translational modifications that regulate protein function. In mitochondria, lysine acylation is predominantly non-enzymatic, and only a specific subset of the proteome is acylated ...
Chris Carrico   +8 more
doaj   +1 more source

Impact of atrial fibrillation on the cognitive decline in Alzheimer’s disease

open access: yesAlzheimer’s Research & Therapy, 2023
Background Atrial fibrillation (AF) is a strong risk factor for Alzheimer’s disease (AD) independent of ischemic stroke. However, the clinicopathological impact of AF on the severity of AD has not been well elucidated.
Taizen Nakase   +8 more
doaj   +1 more source

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

open access: yesNature Communications, 2021
The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces ...
Yanwen Chen   +16 more
doaj   +1 more source

On the Precision of Full-spectrum Fitting of Stellar Populations. III. Identifying Age Spreads [PDF]

open access: yes, 2021
In this third paper of a series on the precision of obtaining ages of stellar populations using the full spectrum fitting technique, we examine the precision of this technique in deriving possible age spreads within a star cluster. We test how well an internal age spread can be resolved as a function of cluster age, population mass fraction, and signal-
arxiv   +1 more source

Expert consensus on neuroimaging diagnosis of dementia and cognitive impairment (2023) [PDF]

open access: yesZhenduanxue lilun yu shijian
For patients with cognitive impairment as the main clinical manifestation, structural MRI (or CT instead) should be performed first to clarify intracranial lesions and brain atrophy.
Aging and Cognitive Impairment Branch of Shanghai Society of Aging and Degenerative Diseases
doaj   +1 more source

Dynamical network stability analysis of multiple biological ages provides a framework for understanding the aging process [PDF]

open access: yes, 2023
Widespread interest in non-destructive biomarkers of aging has led to a curse of plenty: a multitude of biological ages that each proffers a 'true' health-adjusted age of an individual. While each measure provides salient information on the aging process, they are each univariate, in contrast to the "hallmark" and "pillar" theories of aging which are ...
arxiv   +1 more source

Correction for retest effects across repeated measures of cognitive functioning: a longitudinal cohort study of postoperative delirium

open access: yesBMC Medical Research Methodology, 2018
Background Few studies have compared methods to correct for retest effects or practice effects in settings where an acute event could influence test performance, such as major surgery.
Annie M. Racine   +7 more
doaj   +1 more source

Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome

open access: yesDrugs in R&D, 2020
Background Individuals with Down syndrome are likely to develop clinical and neuropathological brain changes resembling Alzheimer’s disease dementia by the ages of 35–40 years.
Michael Rosenbloom   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy